We found that XMU-MP-1 inhibited the growth of ER+ breast cancer cell lines including MCF-7 and T47D in a dose-dependent manner but enhanced the growth of MDA-MB-231, an ER− breast cancer cell line (Fig. 2a, b). This evidence concerns the gene ESR1 and breast carcinoma.